ASX Announcements

Neuren and ACADIA hold Rett syndrome SAB meeting
Change of Director's Interest Notice
FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID
Investor presentation, 6 September 2018
Half Yearly Report and Accounts
Neuren and Lanstead agree to pause settlements for 120 days
Appointment of auditor
Neuren receives initial payment of US$10 million from ACADIA
Change of Director's Interest Notice
Change of Director's Interest Notice